Drugs / Birinapant
Trials 12
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2019-12-16 | Medivir | Results Futility analysis performed of the phase II combination study with birinapant and Keytruda® in colorectal cancer patients medivir.com ↗
IDMC's recommendation is that the study should be terminated as the analysis indicates that it is unlikely that the study's objectives will be met. |
| 2019-06-03 | Medivir | Results New data from the phase I study of birinapant in combination with Keytruda® presented at ASCO medivir.com ↗
Two patients achieved a partial response and seven patients achieved stable disease as best response. |
| 2018-10-04 | Medivir | Results Positive interim data on birinapant in combination with Keytruda® medivir.com ↗
No dose-limiting toxicity has been observed in the first three groups of patients, and the dose escalation has been continued to the highest planned dose level in the study. |
All press releases naming this drug 12 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Birinapant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02756130 ↗ |
| Known as | TL32711 | “Birinapant (TL32711) is a synthetic peptidomimetic antagonist of IAPs (a SMAC-mimetic), which mimics endogenous SMAC resulting in the rapid and irreversible initiation of...” NCT01681368 ↗3“PD) of birinapant (TL32711) when administered in combination with 5-azacitidine” NCT01828346 ↗ “Birinapant (TL32711)” NCT00993239 ↗ |
| Action | Inhibit | “Birinapant (TL32711) is a synthetic peptidomimetic antagonist of IAPs (a SMAC-mimetic), which mimics endogenous SMAC resulting in the rapid and irreversible initiation of...” NCT01681368 ↗ |
| Modality | Small molecule | — CHEMBL3039522 ↗ |
| Route | Intravenous | “30 minute intravenous infusion” NCT00993239 ↗ |